← Klinické štúdie  •  Glomerulopatie

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

Nábor prebieha  •  Fáza 3  •  intervenčná  •  NCT07220083

Stručný súhrn

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.

Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.

Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.

Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Základné údaje

Základné údaje o štúdii
OchoreniaFocal Segmental Glomerulosclerosis
Intervencie DRUG: BI 764198
DRUG: Placebo
SponzorBoehringer Ingelheim
Plánovaný počet286
Začiatok2026-02-16
Predp. ukončenie (primárne)2028-12-27
KrajinyUnited States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, India, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Saudi Arabia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
Posledná aktualizácia2026-06-23
Upozornenie: údaje sú orientačné a podliehajú zmenám. Úplné vstupné/vylučovacie kritériá, kontakty a aktuálny stav nájdete v oficiálnom registri. Tento prehľad nenahrádza lekársku konzultáciu.